A prime-boost regime that combines Montanide ISA720 and Alhydrogel to induce antibodies against the HIV-1 derived multiepitope polypeptide TAB9

Vaccine

Volumn 17, Issue 20-21, 1999, Pages 2646-2650

  Expósito Raya, N éstor ^a   Quintana, Diógenes ^a   Carrazana, Yamilka ^a   Gómez, Carmen E ^a   Duarte, Carlos A ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

Adjuvant; AIDS; Aluminum hydroxide; Cuba; Montanide ISA 720; TAB9; V3 loop

Indexed keywords

ALUMINUM HYDROXIDE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; MONTANIDE ISA 720; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INTRAMUSCULAR DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ALUMINUM HYDROXIDE; ANIMALS; HIV ANTIBODIES; HIV-1; IMMUNIZATION; IMMUNIZATION, SECONDARY; MANNITOL; OLEIC ACIDS; RABBITS; VACCINES, SYNTHETIC;

EID: 0033523051     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00039-0     Document Type: Article

References (21)

1. Walker M.C., Fast P. Clinical trials of candidate AIDS vaccines. AIDS. 8:(Suppl. 1):1994;S213-S236.
2. Esparza J., Heyward W.L., Osmanov S. HIV vaccine development: from basic research to human trials. AIDS. 10:(Suppl. A):1996;S123-S132.
3. Dolin R. Human studies in the development of human immunodeficiency virus vaccines. J. Infec. Dis. 172:1995;1175-1183.
4. Rubinstein A., Goldstein H., Pettoello-Mantovani M., Mizrachi Y., Bloom B., Furer E., Althaus B., Que J.U., Hasler T., Cryz S.J. Safety and immunogenicity of a V3 loop synthetic peptide conjugated to purified protein derivative in HIV-seronegative volunters. AIDS. 9:1995;243-251.
5. Gorse G., Keefer M.C., Belshe R.B., Matthews T.J., Forrest B.D., Hsieh R.H., Koff W.C., Hanson C.V., Dolin R., Weinhold K.J., Frey S.E., Ketler N., Fast P.E. A dose ranging study of a prototype synthetic HIV (MN) branched peptide vaccine. J. Infect. Dis. 173:(2):1996;330-339.
6. Graham B.S. Serological response to candidates AIDS vaccines. AIDS Res. Hum. Retroviruses. 10:(Suppl. 2):1994;S145-148.
7. Montero M., Menéndez A., Domínguez M.C., Navea L., Vilarubia O.L., Quintana D., Izquierdo M., Jiménez V., Reyes O., Lobaina L., Noa E., Duarte C.A. Broadly reactive antibodies against a gp120 V3-loop multiepitope polypeptide neutralize different isolates of human immunodeficiency virus type 1 (HIV-1). Vaccine. 15:(11):1997;1200-1208.
8. Herrera A, Vázquez D, Quintana D, Navea LN, Lobaina L, Nápoles A, Duarte C. Selection of an appropriate adjuvant for vaccination with HIV-1 derived multiepitope polypeptides (MEPs). In: XII International Conference on AIDS, Geneva 1998. Abstract Book: 637, Abstract 33224.
9. Gómez CE, Navea L, Lobaina L, Expósito N, Soto A, Duarte CA. Multiepitope polypeptide TAB9 adjuvated with Montanide ISA720 is highly immunogenic and induces neutralizing antibodies in macaques. Vaccine, in press.
10. Aprile M.A., Wardlaw A.C. Aluminum compounds as adjuvants for vaccine and toxoids in man: a review. Can. J. Publ. Health. 57:1996;343-354.
11. Gupta R.K., Relyeved E.H., Lindblad E.B., Bizzini B., Ben-Efrain S., Gupta C.K. Adjuvants, a balance between toxicity and adjuvanticity. Vaccine. 11:1993;293-306.
12. Gupta R.K., Rost B.E., Relyeved E., Sieber G.R., Newman M.J. Adjuvant properties of aluminum and calcium compounds. Powell M.F., Vaccine design: the subunit approach. 1995;229-248 Plenum Publishing Corporation, New York.
13. Gupta R.K., Sieber G.R. Comparison of adjuvant activities of aluminum phosphate, calcium phosphate and stearyl tyrosine for tetanus toxoid. Biologicals. 22:1994;53-63.
14. Gupta R.K., Sieber G.R. Adjuvants for human use: current status, problems and future prospects. Vaccine. 13:1995;1263-1276.
15. Gupta R.K., Griffin P., Chang A.C., Rivera R., Anderson R., Rost B., Cecchini D., Nicholson M., Siber G.R. The role of adjuvants and delivery systems in modulation of immune response to vaccines. Cohen S., Shafferman A., Novel strategies in design and production of vaccines. 1996;105-113 Plenum Press, New York.
16. Rinella J.V., White J.L., Hem S.L. Treatment of aluminum hydroxide adjuvant to optimize the adsorption of basic proteins. Vaccine. 14:(4):1996;298-300.
17. Bradford M. A rapid and sensitive method for quantitation of microgram quantities of proteins utilizing the principle of protein-dye binding. Annal. Biochem. 72:1976;248.
18. Gómez C.E., López-Campistrous A.E., Duarte C.A. An immunoassay with bovine serum albumin coupled peptides for the improved detection of anti-V3 antibodies in HIV-1+ human sera. J. Virol. Methods. 71:(1):1998;7-16.
19. Cox J.C., Coulter A.R. Adjuvants a classification and review of their modes of action. Vaccine. 15:(3):1997;248-256.
20. Cooper P.D. The selective induction of different immune responses by vaccine adjuvants. Ada G.L., Strategies in vaccine design. 1994;125-158 RG Landes Company.
21. Lawrence G.W., Saul A., Giddy A.J., Kemp R., Pye D. Phase I trial in humans of an oil based adjuvant SEPPIC Montanide ISA720. Vaccine. 15:(2):1997;176-178.